Equities research analysts forecast that CASI Pharmaceuticals Inc (NASDAQ:CASI) will report earnings of ($0.09) per share for the current fiscal quarter, according to Zacks. Zero analysts have provided estimates for CASI Pharmaceuticals’ earnings. CASI Pharmaceuticals posted earnings of ($0.07) per share during the same quarter last year, which suggests a negative year over year growth rate of 28.6%. The company is expected to report its next quarterly earnings results on Tuesday, August 13th.

According to Zacks, analysts expect that CASI Pharmaceuticals will report full-year earnings of ($0.28) per share for the current fiscal year, with EPS estimates ranging from ($0.37) to ($0.17). For the next financial year, analysts expect that the business will report earnings of ($0.17) per share, with EPS estimates ranging from ($0.30) to ($0.03). Zacks Investment Research’s EPS calculations are an average based on a survey of sell-side analysts that that provide coverage for CASI Pharmaceuticals.

CASI Pharmaceuticals (NASDAQ:CASI) last released its quarterly earnings data on Wednesday, May 15th. The biotechnology company reported ($0.09) earnings per share for the quarter, meeting the consensus estimate of ($0.09).

Several research firms recently weighed in on CASI. BidaskClub lowered Amyris from a “hold” rating to a “sell” rating in a research note on Thursday, June 27th. HC Wainwright cut their price target on ImmunoGen from $7.00 to $4.00 and set a “buy” rating on the stock in a research note on Thursday, May 16th.

Several hedge funds have recently made changes to their positions in the company. Geode Capital Management LLC raised its position in shares of CASI Pharmaceuticals by 14.9% during the fourth quarter. Geode Capital Management LLC now owns 584,970 shares of the biotechnology company’s stock worth $2,351,000 after acquiring an additional 75,815 shares during the last quarter. Wellington Shields & Co. LLC raised its position in shares of CASI Pharmaceuticals by 4.3% during the first quarter. Wellington Shields & Co. LLC now owns 1,126,650 shares of the biotechnology company’s stock worth $3,233,000 after acquiring an additional 46,000 shares during the last quarter. Raymond James Financial Services Advisors Inc. raised its position in shares of CASI Pharmaceuticals by 57.8% during the fourth quarter. Raymond James Financial Services Advisors Inc. now owns 60,090 shares of the biotechnology company’s stock worth $242,000 after acquiring an additional 22,000 shares during the last quarter. Rhumbline Advisers raised its position in shares of CASI Pharmaceuticals by 50.3% during the fourth quarter. Rhumbline Advisers now owns 64,395 shares of the biotechnology company’s stock worth $259,000 after acquiring an additional 21,563 shares during the last quarter. Finally, Bank of New York Mellon Corp raised its position in shares of CASI Pharmaceuticals by 12.9% during the fourth quarter. Bank of New York Mellon Corp now owns 172,947 shares of the biotechnology company’s stock worth $695,000 after acquiring an additional 19,781 shares during the last quarter. 11.94% of the stock is currently owned by hedge funds and other institutional investors.

NASDAQ:CASI traded down $0.01 during trading hours on Thursday, hitting $3.12. The company’s stock had a trading volume of 1,903 shares, compared to its average volume of 130,044. The stock has a fifty day simple moving average of $3.12. The stock has a market capitalization of $299.60 million, a P/E ratio of -9.78 and a beta of 1.10. CASI Pharmaceuticals has a twelve month low of $2.73 and a twelve month high of $8.89.

About CASI Pharmaceuticals

CASI Pharmaceuticals, Inc, a pharmaceutical company, develops pharmaceutical products and various therapeutics in China, the United States, and internationally. The company's product pipeline includes EVOMELA, a melphalan hydrochloride for injection primarily for use as a high-dose conditioning treatment prior to hematopoietic progenitor cell transplantation in patients with multiple myeloma.

Further Reading: Management Fee

Get a free copy of the Zacks research report on CASI Pharmaceuticals (CASI)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Receive News & Ratings for CASI Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for CASI Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.